Skip to content
No results
Logo header
  • About ALS
    • Understanding ALS
    • Symptoms/Diagnosis of ALS
    • Treatment of ALS
    • Clinical Care for ALS
    • Resources for People Living With ALS
  • Research
    • Understanding ALS
    • Research Projects
    • Recruiting Researchers
    • Resources for Scientists
  • Our Organization
    • Our Story
    • Packard Center Team
    • Scientific Advisory Board
    • Board of Governors
  • News
Make a Gift

  • Contact Us
Make a Gift
Logo header
  • About ALS
      • Understanding ALS
      • Symptoms/Diagnosis of ALS
      • Treatment of ALS
      • Clinical Care for ALS
      • Resources for People Living with ALS
    • About ALS
      • The Packard Center consists of a group of committed scientists who tackle key questions related to the cause and treatment of ALS. To support their studies, the Center provides expertise, advanced technology, and a highly collaborative spirit.

        Learn More
  • Research
      • Our Approach
      • Understanding ALS
      • Packard Center ALS Strategy
      • Research Projects
      • Partnerships
      • Resources for Scientists
      • The Packard Center ALS Research Strategy is a tried and true approach to accelerate discovery and moving basic/fundamental research towards the clinic.

        Learn More
  • Our Organization
      • About Us
        • Our Story
      • How Funding Works
      • Our Team
        • Packard Center Team
        • Scientific Advisory Board
        • Board of Governors
      • Packard Center Operations
    • Support the Packard Center
      • Through our collaborative ALS research, the Packard Center seeks to unlock ALS. Your generosity helps bring us closer to a cure.

        Make a Gift
      • packark funding event mega menu
  • News
Home » News

  • Contact Us
Make a Gift
Logo header

NEWS


His Mind Helped Rebuild New York. His Body Is Failing Him.
September 12, 2023
Reposted from the NYTimes.comBy Christopher MaagPublished Sept. 6, 2023 Dan Doctoroff once had more power to decide what got built in New York City than anyone since Robert Moses. Now he must contend with a formidable disease. The man pulls the buttoned blue shirt down over his head and waits. His hands, bony, cratered, have lost their […]
Read More >>
Packard Center’s 23rd Annual Symposium brings together established luminaries in ALS research and rising stars from around the world.
July 13, 2023
Hundreds of people in the ALS community gathered in person and online for the 23rd Annual Packard Center Symposium. The meeting was a chance for researchers funded by Packard and others in the scientific world to come together and share their latest research to move the field forward as quickly as possible. More than just […]
Read More >>
AFTD/Packard Center Scientific Meeting Highlights New Collaborations, New Approaches
July 13, 2023
ALS and FTD are complex diseases, with many steps in the disease pathways still unknown. But the two diseases share one major feature in common: In most cases of ALS, and most cases of FTD, vulnerable nerve cells accumulate abnormal clumps of a protein called TDP-43. Because of this common feature, researchers want to know […]
Read More >>
Tara Lincoln joins Packard Center team as new Director, Operations and Administration
July 12, 2023
2023 has been a big year of change for the Packard Center. Besides a new Scientific Director, Packard has also hired a new Director, Operations and Administration. Although Tara Lincoln might be new to the Packard Center, she is not new to ALS.  For the past 12 years, Lincoln has worked behind the scenes at NEALS, […]
Read More >>
Christine Vande Velde Joins Packard Center team as new Science Director
July 10, 2023
Earlier this year, the Packard Center welcomed its new Scientific Director, Dr. Christine Vande Velde. Dr. Vande Velde is a biochemist and cell biologist at the University of Montreal studying how RNA-binding proteins like TDP-43 contribute to ALS. She completed her postdoctoral studies in a Packard-funded lab and is excited to join the Packard team […]
Read More >>
FDA grants accelerated approval of tofersen for treatment of SOD1-ALS
April 27, 2023
The Food and Drug Administration granted accelerated approval of the drug tofersen for the treatment of SOD1-ALS. Developed by Biogen and Ionis, tofersen is an antisense oligonucleotide (ASO) that lowers SOD1 levels in the cell and, hopefully, can help to slow ALS progression. The approval requires the companies to further study tofersen and verify its clinical […]
Read More >>
Research Byte: Packard researchers identify new function of C9 protein
April 26, 2023
In a new paper in PLOS Genetics, Packard researcher Jiou Wang identified a new mechanism through which C9orf72 may cause disease. In order to understand how the mutation in the gene C9orf72—the most common genetic cause of ALS—leads to disease, scientists also need to understand the protein’s normal function. Since the repeat expansion causes a […]
Read More >>
Answer ALS is proud to announce the public release of new in-depth biological and clinical datasets to aid ALS research
April 26, 2023
A new set of Answer ALS project data is now available through the Answer ALS Data Portal. A new set of Answer ALS project data is now available through the Answer ALS Data Portal! The release is a milestone not only for the program but for the field of ALS research in general. This is […]
Read More >>
New links between toxic protein and ALS discovered
April 26, 2023
Neuroscientists at Thomas Jefferson University have identified a new way that repeat expansion in the C9orf72 gene—the most common genetic cause of ALS and FTD—can contribute to ALS. In the years since scientists discovered the repeat expansion in the C9orf72 gene—the most common genetic cause of ALS and FTD—they have learned a lot about how […]
Read More >>
New Phase 2 trial results show promise for ALS
April 26, 2023
Results of a new Phase 2 randomized clinical trial in 137 patients with ALS showed that treatment with the drugs sodium phenylbutyrate and taurursodiol, combined together, could significantly slow functional decline over 24 weeks compared to placebo. Results of a new Phase 2 randomized clinical trial in 137 patients with ALS showed that treatment with […]
Read More >>

Sign up for Packard Center News

Join the Pack

Answer ALS

Pedersen Brain Science Institute

ALS Clinics at Johns Hopkins

Logo footer
John Hopkins Logo

Copyright © 2023 Packard Center
Site by Cornershop Creative   Cornershop Creative logo

  • The John G. Rangos Building
    855 N. Wolf Street Suite 232, Baltimore, MD 21205
  • Contact Us
  • Privacy Policy